Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomised Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of PRTX007 in Normal Healthy Volunteers

Next Previous
X
Search
Trial Profile

A Phase 1, Randomised Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of PRTX007 in Normal Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PRTX 007 (Primary)
  • Indications Cancer; COVID 2019 infections; Hepatitis B; Respiratory syncytial virus infections
  • Focus Adverse reactions; First in man
  • Sponsors Primmune Therapeutics

    • Most Recent Events

    • 14 Nov 2023 Results assessing safety of PRTX007 in healthy volunteers were presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
    • 10 Nov 2023 Results published in the Media Release
    • 10 Nov 2023 According to a Primmune Therapeutics media release, new clinical data were presented at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top